Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.42 |
| ▸ | FURIN | P09958 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.39 |
| ▸ | ACACB | O00763 | 7/20 | 0.38 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | ACACA | Q13085 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16661319 | 0.82 | MIF (0.38) | PARP10FURINNPC1RAB9AKMT2A | |
| SCHEMBL16787728 | 0.78 | CA1 (0.39) | PARP10FURINDGAT1ACACBACACA | |
| SCHEMBL2654775 | 0.76 | NPC1 (0.43) | NPC1RAB9AKMT2A | |
| SCHEMBL22578255 | 0.74 | PARP10 (0.46) | PARP10FURINKMT2AEPHX2FFAR4 | |
| SCHEMBL22463663 | 0.74 | PARP10 (0.46) | PARP10FURINKMT2AEPHX2FFAR4 | |
| SCHEMBL22578254 | 0.74 | PARP10 (0.46) | PARP10FURINKMT2AEPHX2FFAR4 | |
| SCHEMBL13168283 | 0.74 | PARP10 (0.38) | PARP10NPC1RAB9AACACBFFAR1 | |
| SCHEMBL9966865 | 0.74 | PARP10 (0.53) | PARP10FURINEPHX2ACACBALDH1A1 | |
| SCHEMBL22815566 | 0.72 | EPHX2 (0.41) | FURINEPHX2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL30522774 | 0.72 | PARP10 (0.52) | PARP10FURINEPHX2ACACBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170050950-A1 | AROMATIC HETEROCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2017-02-23 | — | — | US | disclosed |
| US-9546155-B2 | Aromatic heterocyclic compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2017-01-17 | — | — | US | disclosed |
| US-20150158844-A1 | AROMATIC HETEROCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2015-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150158844-A1 | AROMATIC HETEROCYCLIC COMPOUND | GPR119, NR0B1, BET1 | PARP10 3877/4885FURIN 2223/4885NPC1 796/4885 |
| US-20170050950-A1 | AROMATIC HETEROCYCLIC COMPOUND | GPR119, NR0B1, BET1 | PARP10 3877/4885FURIN 2223/4885NPC1 796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.